Crescent Biopharma, Inc.CBIONASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
68.42%
↓ 97% below average
Average (39q)
2038.83%
Historical baseline
Range
High:81660.96%
Low:-93.66%
CAGR
+1.5%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 68.42% |
| Q2 2025 | 81660.96% |
| Q1 2025 | -93.66% |
| Q4 2024 | -86.40% |
| Q3 2024 | -72.71% |
| Q2 2024 | 4.32% |
| Q1 2024 | 13.94% |
| Q4 2023 | -0.06% |
| Q3 2023 | 29.93% |
| Q2 2023 | -24.84% |
| Q1 2023 | -8.01% |
| Q4 2022 | 19.66% |
| Q3 2022 | -38.26% |
| Q2 2022 | -16.98% |
| Q1 2022 | -25.52% |
| Q4 2021 | -2.91% |
| Q3 2021 | 30.63% |
| Q2 2021 | -8.79% |
| Q1 2021 | -4.89% |
| Q4 2020 | 9.85% |
| Q3 2020 | 8.09% |
| Q2 2020 | -22.08% |
| Q1 2020 | 10.48% |
| Q4 2019 | 6.93% |
| Q3 2019 | -17.92% |
| Q2 2019 | 10.98% |
| Q1 2019 | -2.21% |
| Q4 2018 | 23.74% |
| Q3 2018 | 4.59% |
| Q2 2018 | 3.11% |
| Q1 2018 | 34.25% |
| Q4 2017 | 16.26% |
| Q3 2017 | 1.01% |
| Q2 2017 | -2.66% |
| Q1 2017 | -3.00% |
| Q4 2016 | 2.35% |
| Q3 2016 | 2.43% |
| Q2 2016 | 4.76% |
| Q1 2016 | -20.72% |
| Q4 2015 | 38.16% |